Literature DB >> 10521086

Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis.

H C Hsu1, W H Tsai, M L Jiang, C H Ho, M L Hsu, C K Ho, S Y Wang.   

Abstract

The regulation of megakaryocytopoiesis and thrombopoiesis appears to be under the control of an array of hematopoietic growth factors. To determine the relationship between endogenous cytokine levels and circulating platelet counts, we measured the serum levels of both thrombopoietic and inflammatory cytokines in the peripheral blood and bone marrow samples from 70 patients with clonal thrombocytosis (CT) caused by myeloproliferative disorders, 28 patients with reactive thrombocytosis (RT), and 35 normal control subjects. The levels of thrombopoietin (TPO), interleukin-6 (IL-6), soluble IL-6 (sIL-6) receptor, IL-11, stem cell factor (SCF), IL-3, and IL-8 were determined by enzyme-linked immunosorbent assay (ELISA). Platelet counts were significantly higher in both CT and patients with RT (699+/-399x10(9)/L, P<.001; 642+/-200 x 10(9)/L, P<.001; respectively) as compared with the normal control subjects (240+/-47x10(9)/L). The concentrations of cytokines in the bone marrow correlated well with those in the peripheral blood. The endogenous levels of TPO, IL-6, and sIL-6 receptor were significantly higher in both CT and patients with RT than those in normal control subjects. The median level of IL-6 was significantly higher in patients with RT than in patients with CT (40 pg/mL vs. 5 pg/mL; P<.001); however, there was no detectable difference in TPO and sIL-6 receptor levels between the two groups. Significantly higher levels of SCF and IL-8 were also found in patients with CT as compared with those found in normal control subjects (median 2460 pg/mL vs 1995 pg/mL, P<.05; 20 ng/mL vs. 5 ng/mL, P = .001; respectively). Finally, IL-11 and IL-3 levels were undetectable in most patients with thrombocytosis. Our results reveal that the endogenous levels of TPO, IL-6, sIL-6 receptor, IL-8, and SCF are elevated in patients with CT or RT. These cytokines appear to be active mediators involved in the regulation of thrombopoiesis during clonal and reactive thrombocytosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10521086     DOI: 10.1016/s0022-2143(99)90154-3

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  15 in total

Review 1.  The molecular mechanisms that control thrombopoiesis.

Authors:  Kenneth Kaushansky
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 2.  Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 3.  It's reticulated: the liver at the heart of atherosclerosis.

Authors:  Prabhakara R Nagareddy; Sunil K Noothi; Michelle C Flynn; Andrew J Murphy
Journal:  J Endocrinol       Date:  2018-05-02       Impact factor: 4.286

Review 4.  Thrombocytosis in the NICU.

Authors:  David J Powner; W Keith Hoots
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

Review 5.  Pathologic thrombopoiesis of rheumatoid arthritis.

Authors:  Ihsan Ertenli; Sedat Kiraz; M Akif Oztürk; Ibrahim c Haznedaroğlu; Ismail Celik; Meral Calgüneri
Journal:  Rheumatol Int       Date:  2003-02-11       Impact factor: 2.631

6.  Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.

Authors:  Jonathan S Bleeker; William J Hogan
Journal:  Thrombosis       Date:  2011-06-08

7.  Platelet count and interleukin 6 gene polymorphism in healthy subjects.

Authors:  J M Fernandez-Real; J Vendrell; C Richart; C Gutierrez; W Ricart
Journal:  BMC Med Genet       Date:  2001-06-01       Impact factor: 2.103

8.  Association between secondary thrombocytosis and viral respiratory tract infections in children.

Authors:  Shou-Yan Zheng; Qiu-Yan Xiao; Xiao-Hong Xie; Yu Deng; Luo Ren; Dai-Yin Tian; Zheng-Xiu Luo; Jian Luo; Zhou Fu; Ai-Long Huang; En-Mei Liu
Journal:  Sci Rep       Date:  2016-03-11       Impact factor: 4.379

9.  TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders.

Authors:  Jan Palmblad; Magnus Björkholm; Jack Kutti; Gerd Lärfars; Eva Löfvenberg; Berit Markevärn; Mats Merup; Nils Mauritzson; Jan Westin; Jan Samuelsson; Gunnar Birgegård
Journal:  Int J Med Sci       Date:  2008-04-13       Impact factor: 3.738

10.  Iron repletion is associated with reduction in platelet counts in non-dialysis chronic kidney disease patients independent of erythropoiesis-stimulating agent use: a retrospective cohort study.

Authors:  Lenar Yessayan; Jerry Yee; Gary Zasuwa; Stan Frinak; Anatole Besarab
Journal:  BMC Nephrol       Date:  2014-07-19       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.